North Carolina-based Inspire Pharmaceuticals announced this morning that Azasite, a drug already approved to treat conjunctivitis, failed to reach the main endpoint in two Phase II clinical trials evaluating it in blepharitis patients. The company says it will conduct additional work to refine trial parameters for an anticipated Phase III program. Inspire's release